Apixaban versus Warfarin in Patients with Atrial Fibrillation
Key result
Apixaban was superior to warfarin in preventing stroke or systemic embolism and caused less bleeding and lower mortality in patients with atrial fibrillation.
Why the study?
Does apixaban prevent stroke or systemic embolism in patients with atrial fibrillation?
Population
Patients with atrial fibrillation
Comparison
apixaban vs warfarin
Design
RCT
Authors
Discussion
Loading...
Member takes
Implication
Apixaban preferred over warfarin in atrial fibrillation; reinforces consensus for NOAC first-line use with lower bleeding and mortality.
Key Points
- This research evaluates the effectiveness of apixaban compared to warfarin in preventing strokes in atrial fibrillation patients.
- Randomized trial design with patients diagnosed with atrial fibrillation
- Participants received either apixaban or warfarin
- Followed patients for outcomes related to stroke, bleeding, and mortality.
- Apixaban significantly reduced stroke or systemic embolism compared to warfarin (exact rates not provided).
- Bleeding episodes were less frequent with apixaban, enhancing safety.
- Mortality rates were lower in the apixaban group, indicating potential long-term benefits.
Structured PICO
Does apixaban prevent stroke or systemic embolism in patients with atrial fibrillation?
P
Population
Patients with atrial fibrillation
I
Intervention
apixaban
C
Comparator
warfarin
O
Outcome
stroke or systemic embolismcomposite
In patients with atrial fibrillation, apixaban is superior to warfarin for preventing stroke or systemic embolism, with the added benefits of less bleeding and lower mortality.
Cite This Study
Granger et al. (2011) studied this question. Apixaban was superior to warfarin in preventing stroke or systemic embolism and caused less bleeding and lower mortality in patients with atrial fibrillation.